Rhodium 研究:中国前沿实验室估值对 ARR 倍数远高于美国同行

Rohan Paul · @rohanpaul_ai · X·2026-09-18 01:35·35分钟前
AI 导读

Rohan Paul 引用 Rhodium 研究称,中国前沿实验室的估值对 ARR 倍数远高于美国同行,Moonshot 约 167x、DeepSeek 约 163x,而 OpenAI 为 34x、Anthropic 为 21x;Moonshot 估值从 2025 年底的 $4B 升至 2026 年 8 月的 $50B。

Rohan Paul@rohanpaul_ai
59AI 编辑部评分,满分 100

Rhodium 研究:中国前沿实验室估值对 ARR 倍数远高于美国同行

2026-09-18 01:35· 35分钟前
AI 导读

Rohan Paul 引用 Rhodium 研究称,中国前沿实验室的估值对 ARR 倍数远高于美国同行,Moonshot 约 167x、DeepSeek 约 163x,而 OpenAI 为 34x、Anthropic 为 21x;Moonshot 估值从 2025 年底的 $4B 升至 2026 年 8 月的 $50B。

Chinese frontier labs are being priced at radically higher revenue multiples than their US peers, per new research from Rhodium.

Moonshot at roughly 167x ARR and DeepSeek at 163x, versus 34x for OpenAI and 21x for Anthropic.

Moonshot’s reported valuation alone surged from $4Bat the end of 2025 to $50B by August 2026. These are specifically valuation-to-ARR multiples, not ordinary trailing-revenue multiples.

The reason is obvious. The denominator is especially weak in China because open-weight distribution limits direct monetization, model prices are dramatically lower, and Chinese customers historically pay less for SaaS and cloud services

Rohan PaulOpenAI and Anthropic earn 10 times more than all Chinese AI models combined, per Rhodium research. OpenAI at roughly $40B in ARR and Anthropic at $65B, while By...